Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Baxter
Medtronic
Johnson and Johnson
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Varespladib methyl

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Varespladib methyl: Sponsors, patents, clinical trial progress

Varespladib methyl is an investigational drug.

There have been 4 clinical trials for Varespladib methyl. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2010.

The most common disease conditions in clinical trials are Syndrome, Acute Coronary Syndrome, and Renal Insufficiency. The leading clinical trial sponsors are Anthera Pharmaceuticals and [disabled in preview].

There are thirty-nine US patents protecting this investigational drug and two hundred and ninety-five international patents.

Recent Clinical Trials for Varespladib methyl
TitleSponsorPhase
A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal FunctionAnthera PharmaceuticalsPhase 1
Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male SubjectsAnthera PharmaceuticalsPhase 1
VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary SyndromeAnthera PharmaceuticalsPhase 3

See all Varespladib methyl clinical trials

Clinical Trial Summary for Varespladib methyl

Top disease conditions for Varespladib methyl
Top clinical trial sponsors for Varespladib methyl

See all Varespladib methyl clinical trials

US Patents for Varespladib methyl

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Varespladib methyl   Start Trial 1H-indole-3-glyoxylamide SPLA.sub.2 inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
Varespladib methyl   Start Trial 1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
Varespladib methyl   Start Trial 1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
Varespladib methyl   Start Trial Process for preparing 1H-indole-3-glyoxylamides Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Varespladib methyl

Drugname Country Document Number Estimated Expiration Related US Patent
Varespladib methyl Austria 220394 2014-04-01   Start Trial
Varespladib methyl Austria 540923 2014-04-01   Start Trial
Varespladib methyl Australia 1621795 2014-04-01   Start Trial
Varespladib methyl Australia 688458 2014-04-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
McKesson
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.